NEW YORK (GenomeWeb News) – Illumina said today that it will partner with Global Genomics Group (G3) to provide whole-genome sequencing for the Genetic Loci and the Burden of Atherosclerotic Lesions, or GLOBAL, clinical trial.

The study aims to identify novel biomarkers and pathways involved in cardiovascular disease to aid in diagnosis, drug development, and a better understanding of the disease.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.